UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in it ...

Predictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Conference Call April 1, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond F. Vennare - CEO and Chairman Josh Blacher - Interim CFO Conference Call Participants Operator Greetings and welcome to the Predictive Oncology Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder this conference is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission file number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaw ...

EXHIBIT 99.1 Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug develop ...

Predictive Oncology Inc. (NASDAQ:POAI) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. And I would now like to hand the conference over to your speaker for today, Mr. Glen ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Dela ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Michael Broadbent - Private Investor Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q1 2023 Earnings Conference Call. [Operator Inst ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Del ...